Levacetylleucine
Based on 1 Customer Validation
Levacetylleucine (N-acetyl-L-leucine), an orally bioavailable and brain-penetrant compound, is an acetylated derivative of amino acid Leucine. Levacetylleucine is the active form of N-acetyl-leucine (NAL). Levacetylleucine attenuates neuronal death and neuroinflammation in the cortical tissue of mice. Levacetylleucine also potentially improves ameliorates lysosomal and metabolic dysfunction. Levacetylleucine improves compensation of postural symptoms after unilateral chemical labyrinthectomy (UL) in rats. Levacetylleucine is promising for research of neurological manifestations of Niemann-Pick disease type C, traumatic brain injury and neurodegeneration prevention.
For research use only. We do not sell to patients.
- Purity: 98.0%
- CAS No.: 1188-21-2
- Formula: C8H15NO3
- Molecular Weight:173.21
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Levacetylleucine (100 mg/kg, oral gavage, administration daily for 28 days) attenuates cortical cell death afer traumatic brain injury (TBI) in N-Acetyl-L-leucine-treated TBI mouse cortices[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague-Dawley rats (mean 400±20 g, age 3 months) after chemical UL[3]
-
Dosage:60 mg/kg
-
Administration:i.v., 15 days
-
Result:Significantly decreased the postural imbalance scores on 7 day and accelerated the course of postural compensation by about 6 days in rats.
-
Animal Model:C57/BL6 mice[4]
-
Dosage:100 mg/kg
-
Administration:oral gavage, administration daily for 1-28 days
-
Result:Did not afect food intake and body weight in mice.
-
Animal Model:N-Acetyl-L-leucine-treated TBI mouse cortices[4]
-
Dosage:100 mg/kg
-
Administration:oral gavage, administration daily for 28 days
-
Result:Prevented cortical cell death which peaks at early time points (day 1) afer TBI in N-Acetyl-L-leucine-treated TBI mouse cortices.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1188-21-2
-
Appearance Solid
-
Molecular Weight 173.21
-
Formula C8H15NO3
-
Color White to off-white
-
SMILES
CC(C)C[C@H](NC(C)=O)C(O)=O
-
Synonyms
N-Acetyl-L-leucine
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Solvent & Solubility
DMSO : 100 mg/mL (577.33 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (14.43 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (14.43 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Bremova-Ertl T, et al. Trial of N-Acetyl-l-Leucine in Niemann-Pick Disease Type C[J]. N Engl J Med. 2024 Feb 1;390(5):421-431. [Content Brief]
[2]. Sarkar C, et al. N-acetyl-L-leucine: a promising treatment option for traumatic brain injury[J]. Neural Regen Res. 2022 Sep;17(9):1957-1958. [Content Brief]
[3]. Günther L, et al. N-acetyl-L-leucine accelerates vestibular compensation after unilateral labyrinthectomy by action in the cerebellum and thalamus[J]. PLoS One. 2015 Mar 24;10(3):e0120891. [Content Brief]
[4]. Hegdekar N, et al. N-Acetyl-L-leucine improves functional recovery and attenuates cortical cell death and neuroinflammation after traumatic brain injury in mice[J]. Sci Rep. 2021 Apr 29;11(1):9249. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.7733 mL | 28.8667 mL | 57.7334 mL | 144.3335 mL |
| 5 mM | 1.1547 mL | 5.7733 mL | 11.5467 mL | 28.8667 mL | |
| 10 mM | 0.5773 mL | 2.8867 mL | 5.7733 mL | 14.4333 mL | |
| 15 mM | 0.3849 mL | 1.9244 mL | 3.8489 mL | 9.6222 mL | |
| 20 mM | 0.2887 mL | 1.4433 mL | 2.8867 mL | 7.2167 mL | |
| 25 mM | 0.2309 mL | 1.1547 mL | 2.3093 mL | 5.7733 mL | |
| 30 mM | 0.1924 mL | 0.9622 mL | 1.9244 mL | 4.8111 mL | |
| 40 mM | 0.1443 mL | 0.7217 mL | 1.4433 mL | 3.6083 mL | |
| 50 mM | 0.1155 mL | 0.5773 mL | 1.1547 mL | 2.8867 mL | |
| 60 mM | 0.0962 mL | 0.4811 mL | 0.9622 mL | 2.4056 mL | |
| 80 mM | 0.0722 mL | 0.3608 mL | 0.7217 mL | 1.8042 mL | |
| 100 mM | 0.0577 mL | 0.2887 mL | 0.5773 mL | 1.4433 mL |
Levacetylleucine Related Classifications
HY-59291 Related Classifications
Powered by Bioz